Sept. 02, 2025 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was presented Sunday, August 31, during an oral presentation at the European Society of Cardiology (ESC) 2025 Congress in Madrid, Spain. It is well-established that the incidence of stroke and myocardial infarction (MI, or heart attack), known collectively as major cardiovascular adverse

Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for dencatistat, a first-in-class, highly selective, orally available CTPS1 inhibitor, demonstrating its versatility as a "pipeline in a product" 2 September 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that the first

Sept. 02, 2025 -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy, today announced the launch of an Expanded Access Treatment Protocol (EAP) to provide continued access to SkinTE® for patients with Wagner 1 diabetic foot ulcers (DFUs). The FDA cleared PolarityBio to initiate this protocol following the successful completion of enrollment in the company’s pivotal Phase

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis 2 September 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces that the first patient has been successfully dosed in its Phase IIa clinical trial “Citydream”. The trial will evaluate CIT-013, a first-in-cla

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; clinical development expected to start 1Q 26 Oncology leadership strengthened with appointment of former Syndax CEO Briggs Morrison, M.D. and Kim Blackwell, M.D. as non-executive directors of the board 2 September 2025 -- CHARM Therapeutics (“CHA

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT1 Patients on Leqvio plus LLT were 43% less likely to experience muscle-related adverse events compared to those on placebo plus LLT1 August 30,

HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial1 Zongertinib recently received Breakthrough Therapy Designation for the first-line treatment of advanced HER2-mutant NSCLC by the Center for Drug Evaluation (CDE) Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been approved as monotherapy by China’s National Medical Products Administration (NMPA) for the treatment of adult patien

– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – Aug. 31, 2025 -- Tourmaline Bio, Inc. (Tourmaline) , a late-stage clinical biotechnology company developing transformative medicines tha

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - Acoramidis also demonstrated a significant 46% hazard reduction in the risk of the composite outcome of CVM or first CVH through 42 months - Acoramidis demonstrated higher rates of disease stabilization or improvement versus disease progression as compared to placebo as reflected in change from base

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated clinically meaningful reductions in office systolic blood pressure at month three with continuous control through month six Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosin